The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Medically reviewed by Corinne Savides Happel, MD Hereditary angioedema (HAE) is a genetic disorder that causes episodes of extreme swelling (angioedema), commonly in the face, hands, feet, digestive ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Hereditary angioedema therapy If fluid loss in your tissues has triggered low blood pressure, you may need large amounts of IV fluids to stay stable. Your doctor may prescribe strong painkillers ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.

Hereditary angioedema affecting the abdomen or oropharynx can be associated with significant risk of illness and death. 2,6 Abdominal attacks can cause severe abdominal pain, nausea, and vomiting ...

KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...

The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...